Research programme: anticancer therapeutics - AstraZeneca/University of Texas M.D. Anderson Cancer Center
Latest Information Update: 28 Mar 2008
At a glance
- Originator AstraZeneca; University of Texas M. D. Anderson Cancer Center
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Mar 2008 Preclinical development is ongoing
- 12 Jan 2006 Preclinical trials in Cancer in USA (unspecified route)